CCR8 and neoplasm: Moreover, when CT26 and MC38 tumor-bearing mice were treated with 225Ac-labeled anti-CCR8 antibody followed by anti-CTLA4 immune-checkpoint-inhibiting immunotherapy, the synergistic slowing down of tumor progression and increase in animal survival were observed [7].